A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan
NCT05228158 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 145
Last updated 2026-01-02
Summary
The primary purpose of the study is to investigate the safety of tazemetostat in participants with relapsed or refractory follicular lymphoma with EZH2 gene mutation under daily clinical practice.
Conditions
- Lymphoma, Follicular
Interventions
- DRUG
-
Tazemetostat
Tazemetostat oral tablets.
Sponsors & Collaborators
-
Eisai Co., Ltd.
lead INDUSTRY
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-08-16
- Primary Completion
- 2028-03-31
- Completion
- 2028-03-31
- FDA Drug
- Yes
Countries
- Japan
Study Locations
More Related Trials
-
FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL
NCT04555811 ·Status: COMPLETED ·Phase: PHASE1
-
A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
NCT02220842 ·Status: COMPLETED ·Phase: PHASE1
-
EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas
NCT07339527 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma
NCT01226849 ·Status: COMPLETED ·Phase: PHASE1
-
Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)
NCT05253118 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
NCT02812706 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
NCT05658562 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
NCT04762160 ·Status: TERMINATED ·Phase: PHASE2
-
A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)
NCT01456039 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
R-ESHAP Followed by Autologous Transplantation for Refractory or Relapsed Diffused Large B-cell Lymphoma
NCT01278602 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
NCT06035497 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
NCT04680052 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
NCT05821088 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
NCT05091541 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma
NCT01208896 ·Status: COMPLETED ·Phase: PHASE2
-
SHR2554 as Maintenance Therapy in Patients With Peripheral T-cell Lymphoma
NCT07347288 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
NCT04998669 ·Status: RECRUITING ·Phase: PHASE2
-
The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk
NCT05018520 ·Status: RECRUITING ·Phase: PHASE3
-
A Single-arm, Multicenter, Prospective Clinical Study of Mitoxantrone Liposome Combined With Chidamide and Azacitidine in the Treatment of Relapsed and Refractory Peripheral T-cell Lymphoma
NCT05495100 ·Status: UNKNOWN ·Phase: PHASE2
-
Comparison of Clinical Outcomes Among Patients Treated With Tisagenlecleucel
NCT05541328 ·Status: COMPLETED
-
Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma
NCT00906841 ·Status: TERMINATED ·Phase: PHASE2
-
Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma
NCT05348213 ·Status: RECRUITING ·Phase: PHASE2
-
Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma
NCT00856245 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)
NCT05137847 ·Status: COMPLETED
-
Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma
NCT05179213 ·Status: UNKNOWN ·Phase: PHASE2